Market Tracker

04/26 5:16pm ET

Infinity Pharmaceuticals Inc (NASDAQ:INFI)

2.14
Delayed Data
As of Apr 26
 +0.07 / +3.38%
Today’s Change
0.84
Today|||52-Week Range
6.43
+58.52%
Year-to-Date
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
Apr 21 / Zacks.com - Paid Partner Content
AMAG Files for FDA Approval of Subcutaneous Form of Makena
Apr 18 / Zacks.com - Paid Partner Content
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
Apr 20 / Zacks.com - Paid Partner Content
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
Apr 18 / Zacks.com - Paid Partner Content
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
Apr 19 / Zacks.com - Paid Partner Content
Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
Apr 17 / Zacks.com - Paid Partner Content
Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report?
Apr 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close2.07
Today’s open2.07
Day’s range2.06 - 2.18
Volume1,113,082
Average volume (3 months)1,145,517
Market cap$104.4M
Dividend yield--
Data as of 3:59pm ET, 04/26/2017

Growth & Valuation

Earnings growth (last year)+76.72%
Earnings growth (this year)--
Earnings growth (next 5 years)+101.00%
Revenue growth (last year)-82.83%
P/E ratioNM
Price/Sales3.58
Price/Book1.26

Competitors

 Today’s
change
Today’s
% change
ARLZAralez Pharmaceutica...+0.11+6.96%
OPHTOphthotech Corp+0.14+4.84%
AGTCApplied Genetic Tech...+0.05+0.85%
RNNRexahn Pharmaceutica...+0.01+2.84%
Data as of 4:02pm ET, 04/26/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)-$0.27
Annual revenue (last year)$18.7M
Annual profit (last year)-$30.1M
Net profit margin-160.77%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Adelene Q. Perkins
President, EVP, Chief Financial &
Business Officer
Lawrence E. Bloch
Corporate headquarters
Cambridge, Massachusetts

Forecasts